

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Varubi (rolapitant hydrochloride) oral capsules

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Varubi (rolapitant hydrochloride) oral capsules	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Varubi (rolapitant hydrochloride) capsules may be approved when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
 - II. Individual is using for prevention of delayed nausea and vomiting associated with initial and repeat courses of one of the following emetogenic cancer chemotherapy: :
 - A. Highly emetogenic chemotherapy (label, NCCN 1); **OR**
 - B. Moderately emetogenic chemotherapy (NCCN 1, NCCN Antiemesis 1.2019);
- AND**
- III. Individual is using in combination with dexamethasone and a 5-HT3 receptor antagonist.

Requests for Varubi (rolapitant hydrochloride) capsules may not be approved for the following:

- I. Individual is taking a CYP2D6 substrate with a narrow therapeutic index (such as, thioridazine and pimozide).

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 27, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 29:4189-4198 . DOI: 10.1200/JCO.2010.34.4614.
6. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on September 27, 2019.
 - a. Antiemesis. V1.2019. Revised February 28, 2019.
 - b. Palliative Care. V2.2019. Revised February 8, 2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.